A-Top Health Biotech Co., Ltd.
TTPEX:7686502.00
TWD
-62.00
(-10.99%)
A-Top Health Biotech Co., Ltd.
TPEX:7686
(Taipei Exchange)
Recent
price
502.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- A-Top Health Biotech Co., Ltd. is a Taiwan-based biotechnology company specializing in human induced pluripotent stem cell (iPSC) technology, high-content phenotypic screening, and precision cellular assay platforms. Founded in 2016 and headquartered in Taipei, Taiwan, the company operates across the biopharmaceutical, contract research, and regenerative medicine sectors. A-Top Health Biotech develops and commercializes advanced biological systems and drug discovery services, comprising patient-derived and gene-edited iPSC lines; differentiated functional cell models, including cardiomyocytes, neural cells, and hepatocytes; automated high-throughput live-cell optical imaging and drug screening platforms; disease modeling and phenotypic drug discovery services for neurodegenerative disorders, cardiovascular conditions, and rare genetic diseases; custom contract research organization (CRO) assay development; in vitro toxicology and safety pharmacology profiling; and personalized drug sensitivity testing solutions for clinical and translational research. The company serves multinational pharmaceutical developers, biotechnology firms, academic research institutes, and clinical organizations across Taiwan, the wider Asia-Pacific region, and North America. In recent operational developments, A-Top Health Biotech has registered its shares on the Taiwan Emerging Stock Board (TPEx: 7686) to support research infrastructure scaling and global commercial expansion. Over the past two years, the company has expanded its strategic alliances with leading academic research institutes, medical centers, and biopharmaceutical partners to co-develop AI-integrated high-content imaging platforms for accelerated compound profiling and drug repurposing. In addition, A-Top Health Biotech has broadened its commercial offering with the launch of next-generation organoid-based microphysiological testing systems and expanded automated cellular toxicology pipelines, strengthening its international contract research capabilities and accelerating preclinical discovery workflows for therapeutic developers.